中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

26 records (took 0.023 seconds)

    Human Anti-Human Influenza Virus Antibody
    3.
    发明申请
    Human Anti-Human Influenza Virus Antibody 有权
    人类抗人流感病毒抗体

    公开(公告)号：US20150044225A1

    公开(公告)日：2015-02-12

    申请号：US14505515

    申请日：2014-10-03

    Applicant: Osaka University ,  The Research Foundation for Microbial Diseases of Osaka University

    Inventor： Kazuyoshi Ikuta ,  Ritsuko Koketsu ,  Yoshinobu Okuno ,  Mikihiro Yunoki ,  Shoji Ideno ,  Masatoshi Oshita ,  Motoki Kuhara ,  Masatoshi Momota

    IPC: C07K16/10

    CPC classification number: C07K16/1018 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/76

    Abstract: Provided is a human antibody having a neutralization activity against a human influenza virus. More specifically, provided is a human antibody which recognizes a highly conserved region in a human influenza A virus subtype H3N2 or a human influenza B virus and has a neutralization activity against the virus. The human antibody is a human anti-human influenza virus antibody, which has a neutralization activity against a human influenza A virus subtype H3N2 and binds to a hemagglutinin HA1 region of the human influenza A virus subtype H3N2, or which has a neutralization activity against a human influenza B virus, and includes, as a base sequence of a DNA encoding a variable region of the antibody, a sequence set forth in any one of SEQ ID NOS: 5 to 12.

    Abstract translation: 本发明提供对人流感病毒具有中和活性的人抗体。 更具体地，提供了识别人流感A型病毒亚型H3N2或人类流感B型病毒中的高度保守区域并具有针对病毒的中和活性的人抗体。 人抗体是人抗流感病毒抗体，其对人甲型流感病毒亚型H3N2具有中和活性，并与人甲型流感病毒亚型H3N2的血凝素HA1区域结合，或者具有中和活性 人流感B病毒，并且作为编码抗体可变区的DNA的碱基序列，包含SEQ ID NO：5〜12中任一项所述的序列。

    BETA CORONAVIRUS COLD ACCLIMATIZED STRAIN AND VACCINE
    5.
    发明公开
    BETA CORONAVIRUS COLD ACCLIMATIZED STRAIN AND VACCINE 审中-公开

    公开(公告)号：US20230374469A1

    公开(公告)日：2023-11-23

    申请号：US18031599

    申请日：2021-10-13

    Applicant: THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY

    Inventor： Shinya OKAMURA ,  Akiho KASHIWABARA ,  Hirotaka EBINA

    IPC: C12N7/00 ,  C07K14/165 ,  A61P31/14

    CPC classification number: C12N7/00 ,  C07K14/165 ,  A61P31/14 ,  A61K2039/5254

    Abstract: Strains that is effective as the active component of a vaccine against the betacoronavirus is provided. A SARS-CoV-2 containing structural protein(s) and/or non-structural protein(s) having the following mutation(s): the amino acid residue mutations in NSP3, corresponding to V at position 404, L at position 445, K at position 1792 and/or D at position 1832 in SEQ ID No. 1; the amino acid residue mutations in NSP14, corresponding to G at position 248, G at position 416, and/or A at position 504 in SEQ ID No. 2; the amino acid residue mutation in NSP16, corresponding to V at position 67 in SEQ ID No. 3; the amino acid residue mutations in the spike, corresponding to L at position 54, T at position 739 and/or A at position 879 in SEQ ID No. 4; the amino acid residue mutation in the envelope, corresponding to L at position 28 in SEQ ID No. 5; and/or, the amino acid residue mutation in the nucleocapsid, corresponding to S at position 2 in SEQ ID No. 6;

    Gene coding for the measles virus mutant antigen
    8.
    发明申请
    Gene coding for the measles virus mutant antigen 失效
    基因编码麻疹病毒突变抗原

    公开(公告)号：US20020146434A1

    公开(公告)日：2002-10-10

    申请号：US09873233

    申请日：2001-06-05

    Applicant: The Research Foundation for Microbial Diseases of Osaka University

    Inventor： Shigeharu Ueda ,  Michiko Watanabe ,  Hitomi Kawanish

    IPC: C07H021/04 ,  A61K039/12 ,  A61K039/165 ,  C12N007/00 ,  C12N007/01 ,  C07K005/00 ,  C07K007/00 ,  C07K016/00 ,  C07K017/00 ,  A61K038/00 ,  C07K001/00 ,  C07K014/00

    CPC classification number: C07K14/005 ,  A61K39/00 ,  A61K2039/51 ,  A61K2039/525 ,  A61K2039/53 ,  C12N2760/18422

    Abstract: Disclosed is a measles virus mutant antigen, comprising at least one protein antigen selected from the group consisting of (I) a measles virus mutant H protein antigen and (II) a measles virus mutant F protein antigen, the measles virus mutant H protein antigen (I) being at least one member selected from the group consisting of the whole protein and fragmentary peptides identified with the positional amino acid numbers of either SEQ ID NO: 2 or SEQ ID NO: 10; and the measles virus mutant F protein antigen (II) 4 being at least one member selected from the group consisting of the whole protein and fragmentary peptides identified with the positional amino acid numbers of either SEQ ID NO: 18 or SEQ ID NO: 20. Also disclosed is a measles virus mutant gene coding for the measles virus mutant antigen. By the use of the measles virus mutant antigen or the gene coding for the same of the present invention, it has become possible to provide efficiently and economically a live attenuated measles vaccine or gene vaccine which is adapted for an epidemic strain of measles virus, and a diagnostic reagent capable of accurately detecting infections with an epidemic strain of measles virus.

    Abstract translation: 公开了一种麻疹病毒突变抗原，其包含选自（I）麻疹病毒突变型H蛋白抗原和（II）麻疹病毒突变F蛋白抗原中的至少一种蛋白质抗原，麻疹病毒突变型H蛋白抗原（ I）是选自由SEQ ID NO：2或SEQ ID NO：10的位置氨基酸编号鉴定的全蛋白和片段肽组成的组中的至少一个; 麻疹病毒突变体F蛋白抗原（II）4是选自由SEQ ID NO：18或SEQ ID NO：20的位置氨基酸编号鉴定的全蛋白和片段肽中的至少一种。 还公开了编码麻疹病毒突变抗原的麻疹病毒突变基因。 通过使用麻疹病毒突变抗原或编码本发明相同的基因，已经有可能高效地和经济地提供适用于麻疹病毒流行株的减毒麻疹疫苗或基因疫苗，以及 能够准确检测麻疹病毒流行病毒感染的诊断试剂。

    Botulinum toxin producing method
    9.
    发明授权
    Botulinum toxin producing method 有权

    公开(公告)号：US11926853B2

    公开(公告)日：2024-03-12

    申请号：US17416342

    申请日：2019-12-17

    Applicant: The Research Foundation For Microbial Diseases of Osaka University

    Inventor： Daisuke Yokouchi ,  Akiko Miura ,  Ryu Okada ,  Yuzo Yamashita ,  Yuya Sasaki ,  Shogo Nishihata

    IPC: C12P21/06 ,  C12N9/52

    CPC classification number: C12N9/52 ,  C12Y304/24069

    Abstract: Provided is a botulinum toxin producing method which is simple achieves a high toxin yield, and obtains a toxin having high specific activity. This botulinum toxin producing method includes: (A) a step in which a botulinum toxin is produced from botulinum toxin-producing bacteria in a medium, and a mixture a is obtained which contains a botulinum toxin, a bacterial component, and a nucleic acid component derived from the botulinum toxin; (B) a step in which the mixture a is subjected to the removal of the bacterial component, and a mixture b is obtained which contains a nucleic acid component and a botulinum toxin; (C) a step in which an endonuclease is added to the mixture b and a mixture c is obtained which contains a nucleic acid degradation product and a botulinum toxin; and (D) a step in which the mixture c is subjected to removal of the nucleic acid degradation product, and an isolated botulinum toxin liquid d is obtained.

    BOTULINUM TOXIN PRODUCING METHOD
    10.
    发明申请
    BOTULINUM TOXIN PRODUCING METHOD 有权

    公开(公告)号：US20220081682A1

    公开(公告)日：2022-03-17

    申请号：US17416342

    申请日：2019-12-17

    Applicant: The Research Foundation For Microbial Diseases of Osaka University

    Inventor： Daisuke Yokouchi ,  Akiko Miura ,  Ryu Okada ,  Yuzo Yamashita ,  Yuya Sasaki ,  Shogo Nishihata

    IPC: C12N9/52

    Abstract: Provided is a botulinum toxin producing method which is simple achieves a high toxin yield, and obtains a toxin having high specific activity. This botulinum toxin producing method includes: (A) a step in which a botulinum toxin is produced from botulinum toxin-producing bacteria in a medium, and a mixture a is obtained which contains a botulinum toxin, a bacterial component, and a nucleic acid component derived from the botulinum toxin; (B) a step in which the mixture a is subjected to the removal of the bacterial component, and a mixture b is obtained which contains a nucleic acid component and a botulinum toxin; (C) a step in which an endonuclease is added to the mixture b and a mixture c is obtained which contains a nucleic acid degradation product and a botulinum toxin; and (D) a step in which the mixture c is subjected to removal of the nucleic acid degradation product, and an isolated botulinum toxin liquid d is obtained.

Patent Agency Ranking